The aim of the research were to obtain of 3-(benzylideneamino)-2-(2,4-
dichlorophenyl)quinazolin-4(3H)-one derivatives and anticancer activity in breast
cancer test on T47D cell.
The compounds are synthesized by three reaction stages. The first stage,
2-aminobenzoic acid was reacted with 2,4-dichlorobenzoyl chloride to obtaining
2-(2,4-dichlorophenyl)-4H-benzo[1,3]oxazin-4-one. The second stage, 2-(2,4-
dichlorophenyl)-4H-benzo[1,3]oxazin-4-one was reacted with hydrazine to
obtaining 3-amino-2-(2,4-dichlorophenyl)quinazolin-4(3H)-one. The third stage,
3-amino-2-(2,4-dichlorophenyl)quinazolin-4(3H)-one was reacted with
benzaldehyde and derivatives such as 4-methoxybenzaldehyde, 4-dimethylaminobenzaldehyde
and 4-nitrobenzaldehyde. The melting point and TLC checks
showed that the compounds are pure and continued for the structural confirmation
test. The results of the confirmation structure of the compounds by the IR spectra,
1HNMR, 13CNMR and MS exhibited the compounds and can be synthesized from
the starting material of 2-aminobenzoic acid with the percentage of yield between
45-53 %. The addition of substituents to the benzaldehyde group affects the length
of reaction time. The duration of reaction time is -N (CH3)2 > -H > -OCH3 >
-NO2.
The 3-(benzylideneamino)-2-(2,4-dichlorophenyl)quinazolin-4(3H)-on
compounds were tested for anticancer activity by MTT method on T47D cells.
The four compounds have weaker anticancer activity than Celecoxib and
predicted to qualitatively inhibit the cyclooxygenase-2 (COX-2) enzyme. The
addition of dimethylamino substituents does not affect anticancer activity,
whereas the addition of nitro substituents will decrease anticancer activity in
T47D breast cancer cells
